Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
Using stem cells to repair damaged hearts is a great story, but proof remains elusive.
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.
Positive data presented Friday, particularly the statistically significant survival benefit favoring patients treated with rindopepimut, has Celldex planning -- cautiously -- for a conversation with the FDA about accelerated approval.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
J&J is paying $35 million upfront to Geron for rights to the drug.
An analysis of results from Oxigene's phase II study of fosbretabulin plus Avastin in recurrent ovarian cancer.
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
A Dendreon agreement calls for a financial restructuring of the company in which the bondholders will receive equity for the debt owed, potentially wiping out current equity shareholders.